Fulcrum Therapeutics (FULC)
FULC · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Genetic Medicinessrc
Signal Snapshot
1
Clinical Trial (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 2
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. — Lancet (2026) PMID 42721980
- Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias. — Blood Adv (2026) PMID 42241705
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Fulcrum Therapeutics.
Full FULC Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.